Is Moderna Stock a Good Investment?
Moderna Investment Advice | MRNA |
- Examine Moderna's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Moderna's leadership team and their track record. Good management can help Moderna navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Moderna's business and its evolving consumer preferences.
- Compare Moderna's performance and market position to its competitors. Analyze how Moderna is positioned in terms of product offerings, innovation, and market share.
- Check if Moderna pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Moderna's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Moderna stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Moderna is a good investment.
Sell | Buy |
Cautious Hold
Market Performance | Weakest | Details | |
Volatility | Very steady | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Moderna Stock
Researching Moderna's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 74.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.17. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Moderna recorded a loss per share of 7.51. The entity had not issued any dividends in recent years. The firm had 1:10 split on the 3rd of August 2017.
To determine if Moderna is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Moderna's research are outlined below:
| Moderna generated a negative expected return over the last 90 days | |
| Moderna has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 3.2 B. Net Loss for the year was (3.56 B) with loss before overhead, payroll, taxes, and interest of (2.2 B). | |
| Moderna currently holds about 8.35 B in cash with (3 B) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 21.73. | |
| Roughly 74.0% of the company shares are owned by institutional investors | |
| Latest headline from benzinga.com: Moderna Stops CMV Program As Vaccine Falls Short In Preventing Infection |
Moderna uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Moderna. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Moderna's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 22nd of February 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 22nd of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Moderna's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Moderna's investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2020-08-05 | 2020-06-30 | -0.35 | -0.31 | 0.04 | 11 | ||
2019-05-08 | 2019-03-31 | -0.36 | -0.4 | -0.04 | 11 | ||
2020-02-26 | 2019-12-31 | -0.42 | -0.37 | 0.05 | 11 | ||
2019-11-06 | 2019-09-30 | -0.43 | -0.37 | 0.06 | 13 | ||
2020-10-29 | 2020-09-30 | -0.43 | -0.59 | -0.16 | 37 | ||
2021-02-25 | 2020-12-31 | -0.35 | -0.69 | -0.34 | 97 | ||
2023-08-03 | 2023-06-30 | -4.04 | -3.62 | 0.42 | 10 | ||
2021-05-06 | 2021-03-31 | 2.39 | 2.84 | 0.45 | 18 |
Moderna Target Price Consensus
Moderna target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Moderna's target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 27 | Buy |
Most Moderna analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Moderna stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Moderna, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationModerna Target Price Projection
Moderna's current and average target prices are 26.74 and 40.30, respectively. The current price of Moderna is the price at which Moderna is currently trading. On the other hand, Moderna's target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Target Price
Analyst Consensus On Moderna Target Price
Moderna Analyst Ratings
Moderna's analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about Moderna stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of Moderna's financials, market performance, and future outlook by experienced professionals. Moderna's historical ratings below, therefore, can serve as a valuable tool for investors.Know Moderna's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Moderna is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Moderna backward and forwards among themselves. Moderna's institutional investor refers to the entity that pools money to purchase Moderna's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Two Sigma Investments Llc | 2025-06-30 | 7 M | Flagship Ventures Management, Inc. | 2025-06-30 | 4.6 M | Ubs Group Ag | 2025-06-30 | 3.9 M | Jane Street Group Llc | 2025-06-30 | 3.8 M | Norges Bank | 2025-06-30 | 3.4 M | Voloridge Investment Management, Llc | 2025-06-30 | 3.4 M | Goldman Sachs Group Inc | 2025-06-30 | 3.4 M | Banque Pictet & Cie Sa | 2025-06-30 | 3.1 M | Northern Trust Corp | 2025-06-30 | 3.1 M | Vanguard Group Inc | 2025-06-30 | 41.7 M | Blackrock Inc | 2025-06-30 | 28.6 M |
Moderna's market capitalization trends
The company currently falls under 'Large-Cap' category with a current market capitalization of 10.44 B.Market Cap |
|
Moderna's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.25) | (0.24) | |
| Return On Capital Employed | (0.33) | (0.31) | |
| Return On Assets | (0.25) | (0.24) | |
| Return On Equity | (0.33) | (0.31) |
Determining Moderna's profitability involves analyzing its financial statements and using various financial metrics to determine if Moderna is a good buy. For example, gross profit margin measures Moderna's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Moderna's profitability and make more informed investment decisions.
Moderna's Earnings Breakdown by Geography
Please note, the presentation of Moderna's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Moderna's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Moderna's management manipulating its earnings.
Evaluate Moderna's management efficiency
Moderna has return on total asset (ROA) of (0.1477) % which means that it has lost $0.1477 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.275) %, meaning that it created substantial loss on money invested by shareholders. Moderna's management efficiency ratios could be used to measure how well Moderna manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to -0.24. The current year's Return On Capital Employed is expected to grow to -0.31. The current year's Net Tangible Assets is expected to grow to about 23.1 B, whereas Total Assets are forecasted to decline to about 9.6 B.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 28.39 | 15.82 | |
| Tangible Book Value Per Share | 28.15 | 15.78 | |
| Enterprise Value Over EBITDA | (4.36) | (4.57) | |
| Price Book Value Ratio | 1.46 | 1.39 | |
| Enterprise Value Multiple | (4.36) | (4.57) | |
| Price Fair Value | 1.46 | 1.39 | |
| Enterprise Value | 33.7 B | 35.4 B |
Leadership effectiveness at Moderna is a strong indicator of its financial stability. We analyze various metrics to provide insights into the stock's investment viability.
Beta 2.007 |
Basic technical analysis of Moderna Stock
As of the 26th of October, Moderna secures the Standard Deviation of 3.14, mean deviation of 2.39, and Risk Adjusted Performance of (0.06). In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Moderna, as well as the relationship between them.Moderna's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Moderna insiders, such as employees or executives, is commonly permitted as long as it does not rely on Moderna's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Moderna insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Stephane Bancel over six months ago Acquisition by Stephane Bancel of 357065 shares of Moderna at 30.96 subject to Rule 16b-3 | ||
Hoge Stephen over six months ago Acquisition by Hoge Stephen of 523 shares of Moderna subject to Rule 16b-3 | ||
James Mock over six months ago Disposition of 1453 shares by James Mock of Moderna subject to Rule 16b-3 | ||
Noubar Afeyan over a year ago Disposition of 2100 shares by Noubar Afeyan of Moderna at 121.5699 subject to Rule 16b-3 | ||
Noubar Afeyan over a year ago Disposition of 7996 shares by Noubar Afeyan of Moderna at 122.0689 subject to Rule 16b-3 | ||
James Mock over a year ago Disposition of 705 shares by James Mock of Moderna at 101.9281 subject to Rule 16b-3 |
Moderna's Outstanding Corporate Bonds
Moderna issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Moderna uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Moderna bonds can be classified according to their maturity, which is the date when Moderna has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View |
Understand Moderna's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Moderna's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.06) | |||
| Market Risk Adjusted Performance | (0.13) | |||
| Mean Deviation | 2.39 | |||
| Coefficient Of Variation | (997.36) | |||
| Standard Deviation | 3.14 | |||
| Variance | 9.86 | |||
| Information Ratio | (0.13) | |||
| Jensen Alpha | (0.50) | |||
| Total Risk Alpha | (0.69) | |||
| Treynor Ratio | (0.14) | |||
| Maximum Drawdown | 12.39 | |||
| Value At Risk | (6.53) | |||
| Potential Upside | 4.98 | |||
| Skewness | (0.04) | |||
| Kurtosis | 0.1605 |
| Risk Adjusted Performance | (0.06) | |||
| Market Risk Adjusted Performance | (0.13) | |||
| Mean Deviation | 2.39 | |||
| Coefficient Of Variation | (997.36) | |||
| Standard Deviation | 3.14 | |||
| Variance | 9.86 | |||
| Information Ratio | (0.13) | |||
| Jensen Alpha | (0.50) | |||
| Total Risk Alpha | (0.69) | |||
| Treynor Ratio | (0.14) | |||
| Maximum Drawdown | 12.39 | |||
| Value At Risk | (6.53) | |||
| Potential Upside | 4.98 | |||
| Skewness | (0.04) | |||
| Kurtosis | 0.1605 |
Consider Moderna's intraday indicators
Moderna intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Moderna stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Moderna Corporate Filings
| 21st of October 2025 Other Reports | ViewVerify | |
| 20th of October 2025 Other Reports | ViewVerify | |
| 15th of October 2025 Other Reports | ViewVerify | |
F4 | 6th of October 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
Moderna Stock media impact
There is far too much social signal, news, headlines, and media speculation about Moderna that are available to investors today. This information is accessible both publicly - through Moderna's media outlets and privately, via word of mouth or internal channels. However, regardless of the source, the sheer volume of Moderna-related data is difficult to distill into actionable insights, especially for investors who are not well-versed in the rapidly evolving tools and techniques of investment management.
A primary focus of Moderna news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Moderna relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Moderna's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Moderna alpha.
Moderna Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Moderna can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Moderna Historical Investor Sentiment
Investor biases related to Moderna's public news can be used to forecast risks associated with an investment in Moderna. The trend in average sentiment can be used to explain how an investor holding Moderna can time the market purely based on public headlines and social activities around Moderna. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Moderna's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Moderna and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Moderna news discussions. The higher the estimate score, the more favorable the investor's outlook on Moderna.
Moderna Maximum Pain Price Across January 16th 2026 Option Contracts
Moderna's options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of Moderna close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of Moderna's options.
Moderna Corporate Management
| Melanie MBA | Chief Officer | Profile | |
| Stephane Bancel | CEO Director | Profile | |
| Dave Johnson | Chief Officer | Profile | |
| Lavina CFA | Senior Relations | Profile | |
| Noubar Afeyan | Independent CoFounder | Profile | |
| Allison MD | Senior Development | Profile |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Moderna. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. For information on how to trade Moderna Stock refer to our How to Trade Moderna Stock guide.You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Moderna. If investors know Moderna will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Moderna listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.85) | Earnings Share (7.51) | Revenue Per Share | Quarterly Revenue Growth (0.41) | Return On Assets |
The market value of Moderna is measured differently than its book value, which is the value of Moderna that is recorded on the company's balance sheet. Investors also form their own opinion of Moderna's value that differs from its market value or its book value, called intrinsic value, which is Moderna's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Moderna's market value can be influenced by many factors that don't directly affect Moderna's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Moderna's value and its price, as these two are different measures arrived at by various means. Investors typically determine if Moderna is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Moderna's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.